The AI-drug-discovery sector in 2026 has split into two camps. One camp wants to design new molecules from first principles. The other wants to make existing pharma R&D faster, cheaper and less likely to fail. The first camp gets the magazine covers. The second camp is closer to a working business.
Owkin sits firmly in…
